NCT02728050View on ClinicalTrials.gov

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

84

Participants

Timeline

Start Date

December 1, 2016

Primary Completion Date

February 3, 2022

Study Completion Date

April 4, 2023

Conditions
Acute Biphenotypic LeukemiaAcute Myeloid Leukemiade Novo Myelodysplastic SyndromeMyelodysplastic SyndromeMyeloproliferative Neoplasm
Interventions
DRUG

Cladribine

Given IV

DRUG

Cytarabine

Given IV

BIOLOGICAL

Filgrastim

Given SC

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

DRUG

Mitoxantrone

Given IV

DRUG

Sorafenib

Given PO

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Bayer

INDUSTRY

lead

University of Washington

OTHER